We thank Dr Ber and Dr Ilan for their comments regarding our recently published commentary regarding recommendations for baseline parameters in nonalcoholic steatohepatitis (NASH) clinical trials.1 We agree with the general concept that liver function is complex and may be altered by multiple pathways such as fibrogenesis, inflammation, oxidative stress, and apoptosis. We further agree conceptually that a change in liver function should be a more clinically important endpoint than an assessment of a pathway, such as a specialized biomarker correlating change of fibrosis.